Events And

EASL International Liver Congress 2022

Jun 25, 2022 at 6:30 PM BST

Oral Presentation: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, Double-Blind, First-in-Human (FIH) Clinical Trial

Speaker: Stephen Harrison, M.D., Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford and Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, TX

Supporting Materials


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail